A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

Phase 1/2 Completed 93 enrolled UCB Biopharma SRL

Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of the study is to characterize the safety and pharmacokinetic (PK) profile of UCB6114 administered as monotherapy or in combination with selected standard of care (SOC) regimens.

Timeline

Start: 2020-07-09
Primary completion: 2024-04-11
Completion: 2024-04-11

Publications

Davies GCG, Dedi N, Jones PS, Kevorkian L, McMillan D, Ottone C, Schulze MED, Scott-Tucker A, Tewari R, West S, Wright M, Rowley TF. Discovery of ginisortamab, a potent and novel anti-gremlin-1 antibody in clinical development for the treatment of cancer. MAbs. 2023 Jan-Dec;15(1):2289681. doi: 10.1080/19420862.2023.2289681. Epub 2023 Dec 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	UCB-6114	Unknown	—	Intravenous
Background	Leucovorin	Small molecule	—	Intravenous
Background	Oxaliplatin	Small molecule	—	Intravenous
Background	Tipiracil	Small molecule	—	—
Background	Trifluridine	Small molecule	—	—
Background	fluorouracil	Small molecule	—	Intravenous

A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

Summary

Timeline

Publications

Drugs

Indications